We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » EC: Scrutiny Leads to Decline in ‘Problematic’ Patent Deals
EC: Scrutiny Leads to Decline in ‘Problematic’ Patent Deals
July 20, 2010
The number of patent settlements between brand- and generic-drug makers considered by the European Commission (EC) to be “potentially problematic” has fallen since the commission increased its scrutiny of the deals, a new report says.